BIOM-09. PROGNOSTIC AND PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS WITH IDHMT TUMORS TREATED IN THE EORTC CATNON TRIAL ON ADJUVANT AND/OR CONCURRENT TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA
Martin J. van den Bent(Erasmus MC Cancer Institute), Pim J. French(Erasmus MC Cancer Institute), B. Baumert(Kantonsspital Graubünden), Anna K. Nowak(The University of Western Australia), Santoesha Ghisai(Erasmus MC), Michael Weller(University Hospital of Zurich), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Sara Erridge(The University of Texas MD Anderson Cancer Center), Mircea Tesileanu(Erasmus MC Cancer Institute), Kenneth Aldape(National Institutes of Health), Helen Wheeler(The University of Sydney), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Vassilis Golfinopoulos(Champalimaud Foundation), Michael A. Vogelbaum(Moffitt Cancer Center), Jean François Baurain(UCLouvain), Paul M. Clément(Universitair Ziekenhuis Leuven), Youri Hoostrate(Erasmus MC), Warren Mason(Princess Margaret Cancer Centre)
Cited by 1
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k